X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DISHMAN PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DISHMAN PHARMA CIPLA/
DISHMAN PHARMA
 
P/E (TTM) x 33.1 25.1 131.8% View Chart
P/BV x 2.9 3.3 86.1% View Chart
Dividend Yield % 0.6 0.7 88.6%  

Financials

 CIPLA   DISHMAN PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-18
DISHMAN PHARMA
Mar-16
CIPLA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs663374 177.1%   
Low Rs479129 371.6%   
Sales per share (Unadj.) Rs189.0197.8 95.6%  
Earnings per share (Unadj.) Rs17.621.2 83.0%  
Cash flow per share (Unadj.) Rs34.034.7 98.0%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %0.50.8 66.1%  
Book value per share (Unadj.) Rs176.7179.9 98.2%  
Shares outstanding (eoy) m805.1280.69 997.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.3 237.4%   
Avg P/E ratio x32.511.9 273.5%  
P/CF ratio (eoy) x16.87.2 231.6%  
Price / Book Value ratio x3.21.4 231.0%  
Dividend payout %17.19.4 180.8%   
Avg Mkt Cap Rs m459,72420,306 2,264.0%   
No. of employees `00023.60.8 2,848.0%   
Total wages/salary Rs m26,9015,355 502.4%   
Avg. sales/employee Rs Th6,446.119,252.7 33.5%   
Avg. wages/employee Rs Th1,139.46,459.5 17.6%   
Avg. net profit/employee Rs Th600.02,064.1 29.1%   
INCOME DATA
Net Sales Rs m152,19315,961 953.6%  
Other income Rs m3,577265 1,347.6%   
Total revenues Rs m155,76916,226 960.0%   
Gross profit Rs m28,2644,103 688.8%  
Depreciation Rs m13,2281,091 1,212.9%   
Interest Rs m1,142944 121.0%   
Profit before tax Rs m17,4702,334 748.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-281 -2,527.3%   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,501624 401.1%   
Profit after tax Rs m14,1661,711 827.9%  
Gross profit margin %18.625.7 72.2%  
Effective tax rate %14.326.7 53.6%   
Net profit margin %9.310.7 86.8%  
BALANCE SHEET DATA
Current assets Rs m108,14111,018 981.5%   
Current liabilities Rs m38,3229,517 402.7%   
Net working cap to sales %45.99.4 487.8%  
Current ratio x2.81.2 243.7%  
Inventory Days Days97110 87.8%  
Debtors Days Days7435 213.6%  
Net fixed assets Rs m109,41116,304 671.1%   
Share capital Rs m1,610161 997.6%   
"Free" reserves Rs m140,68212,907 1,090.0%   
Net worth Rs m142,29214,516 980.3%   
Long term debt Rs m36,6214,189 874.1%   
Total assets Rs m228,60629,805 767.0%  
Interest coverage x16.33.5 469.4%   
Debt to equity ratio x0.30.3 89.2%  
Sales to assets ratio x0.70.5 124.3%   
Return on assets %6.78.9 75.2%  
Return on equity %10.011.8 84.5%  
Return on capital %10.017.5 56.8%  
Exports to sales %32.824.8 132.2%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs m49,8833,956 1,260.9%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m51,6914,952 1,043.9%   
Fx outflow Rs m21,033697 3,018.6%   
Net fx Rs m30,6584,255 720.6%   
CASH FLOW
From Operations Rs m14,6282,786 525.0%  
From Investments Rs m-8,540-1,529 558.6%  
From Financial Activity Rs m-3,855-941 409.6%  
Net Cashflow Rs m2,431316 768.4%  

Share Holding

Indian Promoters % 16.0 61.4 26.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 3.7 329.7%  
FIIs % 23.7 12.7 186.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 22.1 118.6%  
Shareholders   161,166 46,261 348.4%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUN PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  DR. REDDYS LAB  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Healthcare and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued to trade near the dotted line during closing hours and ended the day marginally higher. Gains were largely seen in the healthcare sector .

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

Follow a Super Investor Like This to Multiply Your Wealth(The 5 Minute Wrapup)

Jan 4, 2019

Following a super investor can certainly help build a portfolio and create wealth in the long term.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

HDFC Bank Still Going Strong(Chart Of The Day)

Jan 4, 2019

The stock of HDFC Bank has continued to reward shareholders.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 17, 2019 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS